Pharmaceuticals

Remedy Plan advances RPT1G to Cohort 2 in AML/MDS Phase 1 trial

The Gaithersburg biotech also secured a $30m Series A extension and won FDA IND acceptance for RPT1G in solid tumours.
The Gaithersburg biotech also secured a $30m Series A extension and won FDA IND acceptance for RPT1G in solid tumours.
The Biotech Times Editorial Team  · 
Medical Devices
Digital Health

Flow Neuroscience launches FDA-cleared at-home tDCS device FL-100

Flow Neuroscience's FL-100 headset is now available by US prescription, becoming the first FDA-approved at-home tDCS treatment for moderate to severe
Flow Neuroscience's FL-100 headset is now available by US prescription, becoming the first FDA-approved at-home tDCS treatment for moderate to severe
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Avacta reports clinical proof of mechanism for AVA6103 PDC in FOCUS-01

Avacta's next-generation pre|CISION peptide-drug conjugate showed a clean safety profile and matched preclinical PK predictions across three dose levels in solid
Avacta's next-generation pre|CISION peptide-drug conjugate showed a clean safety profile and matched preclinical PK predictions across three dose levels in solid
The Biotech Times Editorial Team  · 
Digital Health
Medical Devices

NightWare wearable cuts nightmare distress in first responder study

A peer-reviewed pilot in Frontiers in Sleep found NightWare halved nightmare distress in San Francisco police and fire personnel with PTSD over 60 days.
A peer-reviewed pilot in Frontiers in Sleep found NightWare halved nightmare distress in San Francisco police and fire personnel with PTSD over 60 days.
The Biotech Times Editorial Team  · 
Medical Devices
Diagnostics

Senseonics partners Beta Bionics to link Eversense 365 with iLet

Senseonics and Beta Bionics plan to integrate the year-long implantable CGM with the iLet Bionic Pancreas, targeting a commercial launch in Q4 2026.
Senseonics and Beta Bionics plan to integrate the year-long implantable CGM with the iLet Bionic Pancreas, targeting a commercial launch in Q4 2026.
The Biotech Times Editorial Team  · 
Proteomics
Bioinformatics

Seer hits 100 peer-reviewed publications for Proteograph platform

Seer's Proteograph Product Suite has featured in over 100 peer-reviewed studies, spanning disease biology, ageing and population-scale biomarker discovery.
Seer's Proteograph Product Suite has featured in over 100 peer-reviewed studies, spanning disease biology, ageing and population-scale biomarker discovery.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Roche's Lunsumio plus lenalidomide meets Phase III PFS endpoint in FL

Roche's CELESTIMO study showed mosunetuzumab plus lenalidomide significantly improved progression-free survival in relapsed or refractory follicular lymphoma.
Roche's CELESTIMO study showed mosunetuzumab plus lenalidomide significantly improved progression-free survival in relapsed or refractory follicular lymphoma.
The Biotech Times Editorial Team  · 
Medical Devices
Biologics
Pharmaceuticals

EIB and Angelini Ventures hit €48.5m deployed under €150m facility

The EIB-Angelini Ventures co-investment partnership has backed five European life sciences companies in under a year, with €100m expected deployed by early 2027.
The EIB-Angelini Ventures co-investment partnership has backed five European life sciences companies in under a year, with €100m expected deployed by early 2027.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Bioinformatics

X-Chem wins Chordoma Foundation TBXT Challenge with novel binder

X-Chem beat 25 competing teams to become the first to bind Brachyury below 1 micromolar, validating its DEL-based Chemomics platform against a long
X-Chem beat 25 competing teams to become the first to bind Brachyury below 1 micromolar, validating its DEL-based Chemomics platform against a long
The Biotech Times Editorial Team  · 
Cell & Gene Therapy
Biologics

Tempest Therapeutics options Senlang lentiviral in vivo CAR-T platform

Tempest secures an exclusive option on Senlang's CD7-targeted lentiviral vector platform, adding a Phase 1 multiple myeloma programme to its in vivo CAR
Tempest secures an exclusive option on Senlang's CD7-targeted lentiviral vector platform, adding a Phase 1 multiple myeloma programme to its in vivo CAR
The Biotech Times Editorial Team  · 
Medical Devices
Digital Health
Diagnostics

Sonus Microsystems and Medtronic partner on AI wearable for preeclampsia

The Gates Foundation-funded collaboration will run field studies in Kenya, integrating Sonus's autonomous ultrasound patch with Medtronic's patient monitoring platform.
The Gates Foundation-funded collaboration will run field studies in Kenya, integrating Sonus's autonomous ultrasound patch with Medtronic's patient monitoring platform.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Connect Biopharma's rademikibart cuts asthma treatment failure by 66%

Phase 2 data show rademikibart reduced treatment failure and improved lung function in acute asthma, with COPD readout and FDA engagement planned.
Phase 2 data show rademikibart reduced treatment failure and improved lung function in acute asthma, with COPD readout and FDA engagement planned.
The Biotech Times Editorial Team  · 
Subscribe to